A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump

Phase

Condition

Diabetes And Hypertension

Diabetes Mellitus, Type 1

Diabetes Prevention

Treatment

NNC0471-0119 H

Insulin aspart

Clinical Study ID

NCT06809621

NN1471-7712

2024-513472-18

U1111-1306-8005

Ages 18-64
All Genders

Study Summary

The study is looking at the effect and safety of a new fast-acting insulin (NNC0471 0119) to people with type 1 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters your bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The participants will get each study medicine administered at separate clinic visits. The study will last for about 1-3 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female aged 18-64 years (both inclusive) at the time of signing the informedconsent.
Diagnosed with Type 1 Diabetes (T1D) greater than or equal to (≥) 1 year beforescreening.
Insulin administration using continuous subcutaneous insulin infusion via a pumpgreater than or equal to (≥) 90 days before screening.
Current daily insulin treatment between 0.2 and 1.2 Insulin units per kilogram perday [(I)U/kg/day] (both inclusive).

Exclusion

Exclusion Criteria:

Known or suspected hypersensitivity to study intervention(s) or related products.
Female who is pregnant, breast-feeding or intends to become pregnant or is ofchild-bearing potential and not using adequate contraceptive methods.

Study Design